Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Neonatal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%

b) Developmental delay at 18 to 24 months · preterm infants with apnea

Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.86 [0.69, 1.06]
1 study · 715 participants
Moderate

b) Developmental delay at 18 to 24 months · preterm infants prior to extubation

Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.83 [0.68, 1.01]
1 study · 612 participants
Moderate

b) Developmental delay at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.88 [0.78, 1]
1 study · 1725 participants
Moderate